Portage BioTech Inc.

Recent News

  • Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange

    Westport, Connecticut--(Newsfile Corp. - April 16, 2021) -  Portage Biotech Inc., (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). Since Portage's Shares began trading on the NASDAQ Capital Market ("Nasdaq") in February 2021, the majority of active trading has shifted to Nasdaq. Simultaneously, the Company has increased...

    2021-04-16 9:00 AM EDT
  • Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors

    - Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to improve outcomes in a variety of solid tumors Westport, Connecticut--(Newsfile Corp. - April 8, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company"), a clinical-stage immuno-oncology...

    2021-04-08 9:00 AM EDT
  • Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics

    - The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 monthsWestport, Connecticut--(Newsfile Corp. - March 25, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today highlights that Intensity Therapeutics...

    2021-03-25 9:00 AM EDT
  • Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd

    - Out-licensing agreement facilitates focus on the Company's immuno-oncology assets -- Portage may be entitled to up to USD $244 million in future milestone payments -Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage Pharmaceuticals Limited (PPL), including subsidiaries Portage Glasgow Ltd. and EyGen Ltd, to Juvenescence...

    2021-03-04 8:00 AM EST
  • Portage Announces Filing of Third Quarter Financial Statements

    Toronto, Ontario--(Newsfile Corp. - March 2, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immune-oncology company accelerating research and development to overcome immune resistance, today announced the filing of its interim financial statements and related management's analysis and discussion for the period ended December 31, 2020 (the third quarterly filings.) These documents are available from SEDAR, the SEC, and the company's website at www.portagebiotech.com.Highlights for the period and recent weeks...

    2021-03-02 8:00 AM EST
  • Portage Commences Trading on Nasdaq

    Toronto, Ontario--(Newsfile Corp. - February 25, 2021) -  Portage Biotech Inc. (CSE: PBT.U)  (NASDAQ: PRTG) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the commencement of trading of its ordinary shares on the NASDAQ Capital Market ("Nasdaq") under the symbol "PRTG." The Company's ordinary shares will continue to trade on the Canadian Securities Exchange (CSE).As one of the largest exchanges in the world, listing on Nasdaq is considered a...

    2021-02-25 8:00 AM EST
  • Portage Biotech Provides Research and Development Update and Announces NASDAQ Listing Approval

    -- Company to advance three clinical-stage programs in pipeline ---- Portage has received approval and is preparing for NASDAQ listing --Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") today announced its 2021 research and development goals, including advancing three of its pipeline assets through clinical trials during the upcoming year. Portage also announced that it has received approval from the NASDAQ Capital Market ("NASDAQ") to list its common...

    2021-02-11 8:00 AM EST
  • Portage Announces Filing of Q1 Interim Financial Statements; Correction to SalvaRX Loan Note Settlement Announcement

    Toronto, Ontario--(Newsfile Corp. - October 16, 2020) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") announces that the Company has filed its interim financial statements and related management's discussion and analysis for the three-month period ending June 30, 2020 and related delivery requirements (the "Q1 Filings").Previously on August 28, 2020, Portage announced that pursuant to blanket relief granted by the Canadian Securities Administrators, it would not file the Q1 Filings by the filing deadline...

    2020-10-16 4:01 PM EDT